Medicago’s vaccine has generated a strong immune responses in a Phase II trial, which could see it finally reap the benefits of its plant-based technology.

Takeda agreed with its contract manufacturer to grant access to its dengue vaccine production capacity for Johnson & Johnson's COVID-19 vaccine. Frontrunner Moderna started a pediatric trial in children as young as six months. GSK and Medicago began the Phase III portion of a Phase II/III vaccine trial. And China is limiting inbound travel to people vaccinated with China-made vaccines.

Moderna's vaccine has reached the requisite number of cases to trigger a Phase III interim analysis and Brazil allows SinoVac's trial to resume after a serious adverse event, but AstraZeneca's Calquence fails to show any benefit in hospitalized COVID-19 patients. Medicago and GSK also report vaccine progress and the RDIF strikes another production deal.

Allergy Therapeutics is keen to extend its early R&D pipeline into non-allergy areas through extending its tie-up with Saiba and DeepVax on their virus-like particle technology.